Page URL:

Gene test can predict prostate cancer recurrence

14 April 2014
Appeared in BioNews 750

A genetic test has been developed to predict the likelihood of prostate cancer returning after treatment. The test, which looks for 'genetic signatures' often found in recurring cancers, is in the early stages of development but may help doctors better assess treatment options for prostate cancer patients.

'Existing methods for identifying high risk patients are imperfect, so new tests are required that are better at predicting which patients will have their cancer recur', said Professor Robert Bristow of the University of Toronto, presenting data on the test at a radiotherapy conference. 'These men can then be offered additional treatments, such as chemo- and hormone therapy'.

To develop the test, the researchers performed DNA analysis on biopsies of 126 men with prostate cancer before and after surgery and followed their disease progression for an average of eight years.

This helped them identify added and deleted regions of DNA across the genome that typify cancers with a high chance of relapse.

Professor Bristow said: 'This is the first report of a test using this information derived from biopsy samples that can predict with close to 80 percent accuracy which men are at high or low risk of their prostate cancer recurring'.

The researchers also looked at tumours' oxygen content as another potential marker for how the disease would progress. They found that hypoxic, or low-oxygen-level tumours were associated with high levels of relapse.

'Importantly, we found that when we combined the signature with the additional information about the tumour's oxygen content, this made the genetic test even more accurate', Professor Bristow said.

Men with low hypoxia and few genetic changes had a 93 percent chance of being cancer-free after five years. This dropped to 49 percent for men with highly hypoxic tumours and many genetic alterations.

Further trials will be needed to confirm the results and assess the test's clinical usefulness.

16 January 2017 - by Annabel Slater 
Canadian scientists have identified a genetic fingerprint that indicates which prostate cancer tumours may develop into a more aggressive form of the disease after treatment...
19 December 2016 - by Isobel Steer 
A study has cast doubts on the reliability of 'liquid biopsies' – blood tests that detect tumour mutations and are increasingly used to guide treatment...
14 March 2016 - by Dr Lucy Freem 
Scientists have developed a blood test that captures tumour DNA from stray cancer cells circulating in the blood and allows them to monitor genetic changes in skin cancer...
9 November 2015 - by Kirsty Oswald 
Researchers have identified the genetic mutations that drive resistance to the hormone therapy abiraterone in patients with advanced prostate cancer...
3 August 2015 - by Kirsty Oswald 
Researchers have found that prostate cancer can be divided into five subgroups with distinct genetic fingerprints...
24 February 2014 - by Julianna Photopoulos 
Genetic screening could help identify men who are most likely to develop an aggressive form of prostate cancer, a study shows...
15 July 2013 - by Julianna Photopoulos 
Scientists have developed a 'barcode' blood test that reads genetic changes to pick out the most aggressive prostate cancers...
13 May 2013 - by Daryl Ramai 
A genetic test released in the USA claims to be able to score the aggressiveness of prostate cancer before medical intervention, helping men with the condition decide if and when to start receiving treatment....
15 April 2013 - by James Brooks 
Prostate cancer patients who have inherited a well-known gene mutation are more likely to develop an aggressive form of the disease, a study shows...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.